Compound, pharmaceutical composition, methods to inhibit pdgf and lck tyrosine kinase activity, to inhibit mediator release, cell differentiation or proliferation in a patient suffering from a disorder, to treat a pathology linked to a hyperproliferative disorder and restenosis, pdgf tyrosine kinase, and, method for treating inflammation in a patient suffering from such a disorder

摘要

"COMPOUND, PHARMACEUTICAL COMPOSITION, MéTODOSPARA INHIBIT PDGF ACTIVITY AND LCK tyrosine kinase to inhibit release of MEDIATOR, differentiation or proliferation Cell in UMPACIENTE SUFFERING OF A DISTURBANCE TO TRATARUMA PATHOLOGY ON AN DISTúRBIOHIPERPROLIFERATIVO and restenosis, PDGF tyrosine kinase, E, METHOD TO TREAT INFLAMMATION IN A PATIENT SUFFERING SUCH DISTURBANCE ". Stainvention is directed to the quinoline / quinoxaline compounds of formula (I) where X is LIOH or L ~ 2 ~ Z ~ 2 ~; L ~ 1 ~ is (CR ~ 3a ~, R ~ 3b ~) or (CR ~ 3a ~ R ~ 3b ~) ~ m ~ -Z ~ 3 ~ CCR ~ 3 39 a ~ R ~ 3 39 b ~) ~ n ~; L ~ 2 ~ (CR ~ 3a ~ R ~ 3b ~) ~ p ~ -Z ~ 4 ~ - (CR ~ 3 39 a ~ R ~ 3 39 b ~), or ethylene; Z ~ 1 ~ is CH or N; Z ~ 2 ~ is optionally substituted hydroxycycloalkyl, optionally substituted hydroxycycloalkenyl, optionally substituted hydroxyheterocyclyl or optionally substituted hydroxyheterocyclenyl; Z ~ 3 ~ is O, NR ~ 4 ~, S, SO OR SO ~ 2 ~; Z ~ 4 ~ is O, NR ~ 4 ~, S, SO, SO ~ 2 ~ or a bond; m is 0 or 1; n is 2 or 3, and n + m = 2 or 3; p and q are independently 0, 1, 2, 3 or 4, and p + q = 0, 1, 2, 3 or 4 when Z ~ 4 ~ is a bond, and p + q = 0, 1, 2 or 3 when Z ~ 4 ~ is other than a connection; r is 2, 3 or 4; which inhibits platelet-derived growth factor or p56 ^ lck ^ tyrosine kinase activity, for pharmaceutical compositions comprising these compounds, and for the use of these compounds to treat a patient suffering from or subject to disorders / conditions involving cell differentiation, proliferation, extracellular matrix production or release of mediator and / or T cell activation and proliferation